D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156).

	D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156).
	Lu, Shun 4; Zhang, Yiping 5; Zhang, Guojun 6; Zhou, Jianying 7; Cang, Shundong 8; Cheng, Ying 9; Wu, Gang 10; Cao, Peiguo 11; Lv, Dongqing 12; Jin, Xiangming 13
刊名	CANCER RESEARCH
	2021-07-01
卷号	81
ISSN号	0008-5472
WOS研究方向	Oncology
语种	英语
出版者	AMER ASSOC CANCER RESEARCH
WOS记录号	WOS:000680263501326
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/125083]
专题	中国科学院合肥物质科学研究院
作者单位	1.Sichuan Univ, West China Hosp, West China Sch Med, Chengdu, Peoples R China 2.Harbin Med Univ, Canc Hosp, Harbin, Peoples R China 3.Fuzhou Pulm Hosp Fujian, Fuzhou, Peoples R China 4.Shanghai Chest Hosp, Shanghai, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 6.Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China 7.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Peoples R China 8.Henan Prov Peoples Hosp, Zhengzhou, Peoples R China 9.Jilin Canc Hosp, Changchun, Peoples R China 10.Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp Affiliated, Wuhan, Peoples R China
推荐引用方式 GB/T 7714	Lu, Shun,Zhang, Yiping,Zhang, Guojun,et al. D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156).[J]. CANCER RESEARCH,2021,81.
APA	Lu, Shun.,Zhang, Yiping.,Zhang, Guojun.,Zhou, Jianying.,Cang, Shundong.,...&Zhang, Shucai.(2021).D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)..CANCER RESEARCH,81.
MLA	Lu, Shun,et al."D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156).".CANCER RESEARCH 81(2021).